Author Archive: Tracy Cooley

Tracy Cooley

Tracy serves as the Director of Events Communications and handles all communications for BIO’s events and emerging company policy issues. She loves blogging and podcasting on all things biotech and believes in the great potential of the industry, looking for every opportunity to spread the message far and wide. Nearly everyone in her family is a golfer, and as such, she has what many people have called a “natural” swing. Sometimes she even hits the ball. Tracy just finished her ninth marathon, and has nearly mastered the skill of one-foot-in-front-of-the-other (usually, sometimes the laces get in the way). The joy of her life is her five-year-old daughter Josephine.

Latest Posts

ISO: Biotech Humanitarian

We are looking for biotech humanitarians for our annual Biotech Humanitarian Award. The award recognizes an everyday hero who has helped to heal, fuel or feed the planet through their work in biotechnology. Know someone that you feel should be recognized for their good works? Nominate someone at through January 31, 2010. 2009 Biotech Humanitarian Dr. Jay Keasling, was nominated by a colleague at the University of California at Berkley. Just think, you or your Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , ,

The booming H1N1 vaccine market

The vaccine market is booming – and biotech companies are just one of the beneficiaries.  A recent Associated Press Article explains that an increase in government support and newer, better technologies are just a part of it.  Patients look to benefit from new vaccinations on the horizon for diseases such as Alzheimer’s, herpes, malaria, and perhaps even a universal flu vaccine. It was just last month at the BIO Investor Forum’s H1N1 panel that panelists Read More >

Business of Biotech  |  1 Comment  |  Email This Post
Tags: , ,

Panelists make it personal

Panelists in the “Making it Personal” session discussed the clinical utility, comparative effectiveness implications and reimbursement for personalized medicine. Tod Klinger, PhD of XDx, Inc. asserted that we are still in the early stages of personalized medicine since there is a need to determine how to link measurements with relevant clinical information for the patient to enable decision making. Furthermore, there are many other questions that still need to be considered. Ellen Sheets, MD, of Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

The race against pandemic flu

Panelists at this morning’s Therapeutic Workshop, “Predicting a Frontrunner in the Race Against Pandemic Flu” had many valuable insights into this year’s flu pandemic, how it has compared to past pandemics, and how it will shape vaccine manufacturing in the years to come. According to Dr. Tomás Aragón, Executive Director at the Center for Infectious Disease & Emergency Readiness, “Virulence [of H1N1] is no worse than the regular flu, but a larger risk pool, consisting Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Endocyte awarded patent for vitamin receptor binding drug delivery conjugates

Endocyte, Inc. has been awarded a patent from the United States Patent and Trademark Office covering vitamin receptor binding anti-cancer agents. The patent, entitled “Vitamin Receptor Binding Drug Delivery Conjugates” (U.S. Patent No. 7,601,332), covers novel conjugation linkages and anti-cancer agents, including Endocyte’s EC145, which is currently in development as a potential treatment for ovarian and non-small cell lung cancers.

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,